MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 7,416 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lowered its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 1.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 631,134 shares of the company’s stock after selling 7,416 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in PROCEPT BioRobotics were worth $50,819,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Graham Capital Management L.P. purchased a new stake in PROCEPT BioRobotics in the 4th quarter worth about $230,000. Ensign Peak Advisors Inc increased its holdings in PROCEPT BioRobotics by 1.1% in the 4th quarter. Ensign Peak Advisors Inc now owns 14,165 shares of the company’s stock worth $1,141,000 after acquiring an additional 150 shares during the last quarter. Frontier Capital Management Co. LLC purchased a new stake in PROCEPT BioRobotics in the 4th quarter worth about $18,145,000. Deutsche Bank AG increased its holdings in PROCEPT BioRobotics by 54.6% in the 4th quarter. Deutsche Bank AG now owns 145,242 shares of the company’s stock worth $11,695,000 after acquiring an additional 51,289 shares during the last quarter. Finally, Corton Capital Inc. purchased a new stake in PROCEPT BioRobotics in the 4th quarter worth about $295,000. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PRCT. Truist Financial decreased their price objective on PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating for the company in a report on Friday, April 11th. Morgan Stanley reduced their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Finally, Bank of America reduced their target price on PROCEPT BioRobotics from $104.00 to $84.00 and set a “buy” rating for the company in a report on Friday, April 25th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $90.00.

Insider Activity

In related news, CEO Reza Zadno sold 5,475 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the sale, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. The trade was a 3.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin Waters sold 733 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares of the company’s stock, valued at $6,161,966.46. The trade was a 0.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,455 shares of company stock worth $368,322. 6.60% of the stock is currently owned by insiders.

PROCEPT BioRobotics Stock Down 2.6%

PRCT stock opened at $53.04 on Wednesday. The firm has a market capitalization of $2.93 billion, a PE ratio of -27.20 and a beta of 1.10. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The stock has a 50-day simple moving average of $55.33 and a two-hundred day simple moving average of $72.66. PROCEPT BioRobotics Co. has a twelve month low of $47.04 and a twelve month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.04. The firm had revenue of $69.16 million during the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.51) EPS. On average, equities analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).